ArticleDiscover oncology2025
Demographic and clinical predictors of treatment outcomes in invasive lobular carcinoma breast cancer: insights from Cox regression analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive lobular carcinoma (ILC) ranks as the second most prevalent type of breast cancer after invasive ductal carcinoma (IDC). Understanding the demographics, clinical, and treatment outcomes of patients with ILC is essential for developing personalized treatment strategies. The purpose of this study is to evaluate the risk factors, treatment efficacy, demographics, and effects of marital status on treatment approaches for patients with lobular carcinoma. The data retrieved from the SEER program included 2,085 patients with lobular carcinoma. Descriptive statistics describe their clinical and demographical characteristics, while inferential statistics, including the Pearson chi-square test and Cox regression models, assess treatment outcomes based on age and clinicopathological factors. Among the cohort, 7.9% of patients were aged 30-44, 40.1% were aged 45-59, and 52% were aged 60-74. The analysis indicated that patients aged 45-59 predominantly received radiation therapy, while those aged 60-74 primarily underwent chemotherapy. Compared to older individuals, younger patients demonstrated a more favorable response to chemotherapy (HR = 0.653, 95% CI: 0.261-1.633) and radiation therapy (HR = 0.625, 95% CI: 0.249-1.565). Age at diagnosis was an independent factor in breast cancer of lobular carcinoma. The Cox regression models revealed significant disparities in treatment effects across different age groups and clinicopathological characteristics. The chi-square analysis showed no significant associations for most variables, indicating that unmeasured factors influence chemotherapy and radiation therapy. A frailty model better captures risk factors, improving treatment decision-making and patient outcome analysis. This study emphasizes the need to evaluate demographic and clinical factors in treatment planning for lobular carcinoma patients. The findings suggest that personalized treatment strategies should be developed to address the varying responses to treatment among different patient cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.